Lifeline Biotechnologies granted US patent for OvaScope technology

According to Lifeline Biotechnologies, OvaScope has been designed and developed to assist in the early detection of ovarian cancer. To date, the preliminary testing has proved to be promising.

Lifeline will begin taking the next steps toward bringing the OvaScope to market upon completion of its current review of the testing data results and the market for the product.

Jim Holmes, CEO of Lifeline Biotechnologies, said: “It is estimated that 1 in 70 women in the US will develop ovarian cancer during their lifetime. Unfortunately, detection usually occurs in the late stages, leading to poor survival rates.

“With a US patent and very encouraging results from our preliminary testing, we feel the OvaScope has the ability to address this issue and make tremendous strides towards early detection of ovarian cancer. If we can detect this cancer in its early stages, it will dramatically increase the potential survival rate for women.”